Skip to main content

Posters

October 09, 2020
In 2 placebo-controlled studies of adults with attention-deficit/hyperactivity disorder (ADHD), SHP465 mixed amphetamine salts (MAS) extended-release significantly reduced ADHD-Rating Scale IV total score (ADHD-RS-IV-TS) versus placebo. The current post hoc analyses examined SHP465 MAS treatment…
November 22, 2019
In adults with attention-deficit/hyperactivity disorder (ADHD), reductions in ADHD-Rating Scale-IV total score (ADHD-RS-IV-TS) were significantly greater with SHP465 mixed amphetamine salts (MAS) extended-release than placebo. These post hoc analyses examined SHP465 MAS remission rates from 2…
November 22, 2019
Purpose: Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to provide treatment effect in the early morning, throughout the day, and into the evening. Herein, we present the efficacy and safety of DR/ER-MPH from a pivotal phase 3 study of 125…
November 22, 2019
Purpose: Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to provide treatment effect in the early morning, throughout the day, and into the evening. This pivotal, phase 3, forced-dose titration trial sought to determine whether DR/ER-MPH improves…
November 22, 2019
Purpose: Sleep disturbances are associated with attention-deficit/hyperactivity disorder (ADHD) and methylphenidate (MPH) treatment. We assessed whether sleep-related adverse event (AE) rates are affected by sample and study design features of trials evaluating MPH in youth with ADHD.
November 22, 2019
Adult attention-deficit/hyperactivity disorder (ADHD) can affect work productivity. This survey examined relationships between oral stimulant medication adherence, work productivity and related indirect costs, and ADHD symptom level among US adults diagnosed with ADHD.
November 22, 2019
Adult attention-deficit/hyperactivity disorder (ADHD) is associated with impaired executive function (EF). This post hoc analysis examines relationships between changes in ADHD symptoms and EF, as measured by the ADHD-Rating Scale-IV (ADHD-RS-IV) and Brown Attention-Deficit Disorder Scale (BADDS),…
November 22, 2019
Objective: Determine if AMPH EROS has an onset of effect at 30 minutes post-dose in children with ADHD.
November 22, 2019
Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for attention-deficit/hyperactivity disorder (ADHD). Here we present results of a Phase 3, randomized, double-blind, placebo-…
November 22, 2019
Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for pediatric attention-deficit/hyperactivity disorder (ADHD). Here we present results of a Phase 3, randomized, double-blind,…
Back to Top